PURPOSE: We evaluated the correlation between the expression of CXCR4 and prognostic factors in patients with prostate cancer. MATERIALS AND METHODS: A total of 57 patients who had undergone surgery for prostate cancer were enrolled. Specimens were obtained before any treatment and were stained with antihuman CXCR4 antibody. The intensity of staining was graded as low or high. The age, pretreatment prostate-specific antigen (PSA) level, Gleason score, T stage, biochemical recurrence, local recurrence, and distant metastasis were compared according to the expression of CXCR4 in patients with prostate cancer. RESULTS: Local recurrence was higher in the group with high expression, in 11 of 36 cases (30.6%), than in the group with low expression, in 1 of 21 cases (4.8%), with statistical significance (p=0.040). Distant metastasis was also associated with expression, occurring in 10 of 36 cases (27.8%) in the group with high expression and in 1 of 21 cases (4.8%) in the group with low expression (p=0.041). In the logistic regression test, CXCR4 expression was the only factor in determining local recurrence (p=0.016) and distant metastasis (0.022). Furthermore, the group with high CXCR4 expression showed significantly longer cancer-specific survival than did the low expression group (p=0.041). CXCR4 showed no association with age (p=0.881), pretreatment PSA level (p=0.584), Gleason score (p=0.640), T stage (p=0.967), or biochemical recurrence (p=0.081). CONCLUSIONS: The high expression of CXCR4 was associated with local recurrence and distant metastasis. CXCR4 expression was shown to be a useful prognostic factor for patients with prostate cancer.
PURPOSE: We evaluated the correlation between the expression of CXCR4 and prognostic factors in patients with prostate cancer. MATERIALS AND METHODS: A total of 57 patients who had undergone surgery for prostate cancer were enrolled. Specimens were obtained before any treatment and were stained with antihuman CXCR4 antibody. The intensity of staining was graded as low or high. The age, pretreatment prostate-specific antigen (PSA) level, Gleason score, T stage, biochemical recurrence, local recurrence, and distant metastasis were compared according to the expression of CXCR4 in patients with prostate cancer. RESULTS: Local recurrence was higher in the group with high expression, in 11 of 36 cases (30.6%), than in the group with low expression, in 1 of 21 cases (4.8%), with statistical significance (p=0.040). Distant metastasis was also associated with expression, occurring in 10 of 36 cases (27.8%) in the group with high expression and in 1 of 21 cases (4.8%) in the group with low expression (p=0.041). In the logistic regression test, CXCR4 expression was the only factor in determining local recurrence (p=0.016) and distant metastasis (0.022). Furthermore, the group with high CXCR4 expression showed significantly longer cancer-specific survival than did the low expression group (p=0.041). CXCR4 showed no association with age (p=0.881), pretreatment PSA level (p=0.584), Gleason score (p=0.640), T stage (p=0.967), or biochemical recurrence (p=0.081). CONCLUSIONS: The high expression of CXCR4 was associated with local recurrence and distant metastasis. CXCR4 expression was shown to be a useful prognostic factor for patients with prostate cancer.
Authors: Takashi Kijima; Gautam Maulik; Patrick C Ma; Elena V Tibaldi; Ross E Turner; Barrett Rollins; Martin Sattler; Bruce E Johnson; Ravi Salgia Journal: Cancer Res Date: 2002-11-01 Impact factor: 12.701
Authors: Matthew C P Smith; Kathryn E Luker; Joel R Garbow; Julie L Prior; Erin Jackson; David Piwnica-Worms; Gary D Luker Journal: Cancer Res Date: 2004-12-01 Impact factor: 12.701
Authors: M Takenaga; H Tamamura; K Hiramatsu; N Nakamura; Y Yamaguchi; A Kitagawa; S Kawai; H Nakashima; N Fujii; R Igarashi Journal: Biochem Biophys Res Commun Date: 2004-07-16 Impact factor: 3.575
Authors: Jun Wang; Liqiang Xi; Jennifer L Hunt; William Gooding; Theresa L Whiteside; Zhuo Chen; Tony E Godfrey; Robert L Ferris Journal: Cancer Res Date: 2004-03-01 Impact factor: 12.701
Authors: J-P Spano; F Andre; L Morat; L Sabatier; B Besse; C Combadiere; P Deterre; A Martin; J Azorin; D Valeyre; D Khayat; T Le Chevalier; J-C Soria Journal: Ann Oncol Date: 2004-04 Impact factor: 32.976
Authors: Kathleen C Light; Neeraj Agarwal; Eli Iacob; Andrea T White; Anita Y Kinney; Timothy A VanHaitsma; Hannah Aizad; Ronald W Hughen; Lucinda Bateman; Alan R Light Journal: Psychoneuroendocrinology Date: 2013-09-06 Impact factor: 4.905
Authors: Nicolas Barry Delongchamps; Frédéric Beuvon; Jacques R R Mathieu; Stéphanie Delmas; Isabelle Metzger; Hervé Prats; Florence Cabon Journal: World J Urol Date: 2014-04-19 Impact factor: 4.226
Authors: M Katie Conley-LaComb; Allen Saliganan; Pridvi Kandagatla; Yong Q Chen; Michael L Cher; Sreenivasa R Chinni Journal: Mol Cancer Date: 2013-07-31 Impact factor: 27.401